Rosuvastatin tablets are an HMG Co-A reductase inhibitor (statin) indicated: (1)
• To reduce the risk of major adverse cardiovascular (CV) events (CV death, nonfatal myocardial infarction, nonfatal stroke, or an arterial revascularization procedure) in adults without established coronary heart
disease who are at increased risk of CV disease based on age, high-sensitivity C-reactive protein (hsCRP) ≥2 mg/L, and at least one additional CV risk factor.
• As an adjunct to diet to:
- reduce LDL-C in adults with primary hyperlipidemia.
- reduce LDL-C and slow the progression of atherosclerosis in adults.
- reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
• As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH).
• As an adjunct to diet for the treatment of adults with:
- Primary dysbetalipoproteinemia.
-Hypertriglyceridemia.
